תקציר
The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation. Its safety and efficacy have not been previously evaluated in children. A retrospective analysis of 15 pediatric bone marrow transplant patients who had amlodipine incorporated into their antihypertensive drug regimen reveals significantly lower blood pressure as compared with baseline therapy (123.5 ± 2.1 mmHg and 117.2 ± 2.2 mmHg, systolic blood pressure before and during amlodipine, P<0.05; 81.5 ± 1.8 mmHg and 75.5 ± 2.6 mmHg, diastolic blood pressure before and during amlodipine, P<0.05). Amlodipine provided improved blood pressure control in this cohort and may provide a valuable pharmacologic alternative for treatment of pediatric hypertension.
שפה מקורית | אנגלית |
---|---|
עמודים (מ-עד) | 31-36 |
מספר עמודים | 6 |
כתב עת | Clinical Pediatrics |
כרך | 37 |
מספר גיליון | 1 |
מזהי עצם דיגיטלי (DOIs) | |
סטטוס פרסום | פורסם - 1998 |
פורסם באופן חיצוני | כן |